SCHEMBL9681883

SCHEMBL9681883

CCNC(=O)OCC(O)CO

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
KDM4E B2RXH2 1/20 0.47
DUSP3 P51452 1/20 0.47
LMNA P02545 1/20 0.47
CHRNB2 P17787 1/20 0.43
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
CHRNA4 P43681 1/20 0.43
DGKA P23743 1/20 0.41
FAAH O00519 4/20 0.39
ALDH1A1 P00352 1/20 0.39
USP2 O75604 1/20 0.36
ACHE P22303 2/20 0.35
EPHX1 P07099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17807372 0.90 SMN1; SMN2 (0.53) SMN1; SMN2MEN1KMT2AKDM4EDUSP3
SCHEMBL10068346 0.86 SMN1; SMN2 (0.54) SMN1; SMN2MEN1KMT2AKDM4EDUSP3
SCHEMBL17790870 0.85 MEN1 (0.49) MEN1KMT2AKDM4EDUSP3LMNA
SCHEMBL17793929 0.82 SMN1; SMN2 (0.39) SMN1; SMN2MEN1KMT2AKDM4EDUSP3
SCHEMBL9683934 0.82 ACHE (0.59) MEN1KMT2AKDM4EDUSP3LMNA
SCHEMBL17793921 0.82 LMNA (0.42) SMN1; SMN2MEN1KMT2AKDM4EDUSP3
SCHEMBL19355185 0.81 CYP2D6 (0.42) SMN1; SMN2MEN1KMT2AKDM4EDUSP3
SCHEMBL17794032 0.80 LMNA (0.41) SMN1; SMN2MEN1KMT2AKDM4EDUSP3
SCHEMBL1416460 0.80 LMNA (0.40) SMN1; SMN2MEN1KMT2AKDM4EDUSP3
SCHEMBL17791085 0.80 LMNA (0.40) SMN1; SMN2MEN1KMT2AKDM4EDUSP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170258741-A1 FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY CATABASIS PHARMACEUTICALS, INC. (US) 2017-09-14 US disclosed
US-5158808-A Method of coating with a water borne composition UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 1992-10-27 US disclosed
US-5039759-A Water borne high solids coating compositions TECHNOLOGY CORPORATION UNITED CARBIDE CHEMICALS AND PLASTICS (US) 1991-08-13 US disclosed
EP-0212380-B1 AQUEOUS HIGH SOLIDS COATING COMPOSITIONS UNION CARBIDE CORPORATION (US) 1990-09-19 EP disclosed
US-4677168-A Water borne high solids coating compositions UNION CARBIDE CORPORATION, 1987-06-30 US disclosed
EP-0212380-A2 Aqueous high solids coating compositions UNION CARBIDE CORPORATION (US) 1987-03-04 EP disclosed
EP-0211359-A1 High solids coating compositions UNION CARBIDE CORPORATION (US) 1987-02-25 EP disclosed
EP-0196112-A2 Aqueous high solids coating compositions UNION CARBIDE CORPORATION (US) 1986-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170258741-A1 FATTY ACID CYSTEAMINE CONJUGATES AND THEIR USE AS ACTIVATORS OF AUTOPHAGY NDUFAB1, ATG7, HADHA SMN1; SMN2 229/4885MEN1 2656/4885KMT2A 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.